Literature DB >> 19566274

Delayed and lasting effects of deep brain stimulation on locomotion in Parkinson's disease.

Anne Beuter1, Julien Modolo.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a variety of motor signs affecting gait, postural stability, and tremor. These symptoms can be improved when electrodes are implanted in deep brain structures and electrical stimulation is delivered chronically at high frequency (>100 Hz). Deep brain stimulation (DBS) onset or cessation affects PD signs with different latencies, and the long-term improvements of symptoms affecting the body axis and those affecting the limbs vary in duration. Interestingly, these effects have not been systematically analyzed and modeled. We compare these timing phenomena in relation to one axial (i.e., locomotion) and one distal (i.e., tremor) signs. We suggest that during DBS, these symptoms are improved by different network mechanisms operating at multiple time scales. Locomotion improvement may involve a delayed plastic reorganization, which takes hours to develop, whereas rest tremor is probably alleviated by an almost instantaneous desynchronization of neural activity in subcortical structures. Even if all PD patients develop both distal and axial symptoms sooner or later, current computational models of locomotion and rest tremor are separate. Furthermore, a few computational models of locomotion focus on PD and none exploring the effect of DBS was found in the literature. We, therefore, discuss a model of a neuronal network during DBS, general enough to explore the subcircuits controlling locomotion and rest tremor simultaneously. This model accounts for synchronization and plasticity, two mechanisms that are believed to underlie the two types of symptoms analyzed. We suggest that a hysteretic effect caused by DBS-induced plasticity and synchronization modulation contributes to the different therapeutic latencies observed. Such a comprehensive, generic computational model of DBS effects, incorporating these timing phenomena, should assist in developing a more efficient, faster, durable treatment of distal and axial signs in PD.

Entities:  

Mesh:

Year:  2009        PMID: 19566274     DOI: 10.1063/1.3127585

Source DB:  PubMed          Journal:  Chaos        ISSN: 1054-1500            Impact factor:   3.642


  6 in total

1.  A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD.

Authors:  R J St George; J G Nutt; K J Burchiel; F B Horak
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

2.  The effects of subthalamic and pallidal deep brain stimulation on postural responses in patients with Parkinson disease.

Authors:  Rebecca J St George; Patricia Carlson-Kuhta; Kim J Burchiel; Penelope Hogarth; Nicholas Frank; Fay B Horak
Journal:  J Neurosurg       Date:  2012-03-16       Impact factor: 5.115

3.  Effects of deep brain stimulation in the subthalamic nucleus or globus pallidus internus on step initiation in Parkinson disease: laboratory investigation.

Authors:  Laura Rocchi; Patricia Carlson-Kuhta; Lorenzo Chiari; Kim J Burchiel; Penelope Hogarth; Fay B Horak
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

4.  Neuromodulation of the cerebellum rescues movement in a mouse model of ataxia.

Authors:  Lauren N Miterko; Tao Lin; Joy Zhou; Meike E van der Heijden; Jaclyn Beckinghausen; Joshua J White; Roy V Sillitoe
Journal:  Nat Commun       Date:  2021-02-26       Impact factor: 14.919

5.  Electrophysiological Signature and the Prediction of Deep Brain Stimulation Withdrawal and Insertion Effects.

Authors:  Carlos Trenado; Laura Cif; Nicole Pedroarena-Leal; Diane Ruge
Journal:  Front Neurol       Date:  2021-11-30       Impact factor: 4.003

6.  Effects of a 60 Hz Magnetic Field Exposure Up to 3000 μT on Human Brain Activation as Measured by Functional Magnetic Resonance Imaging.

Authors:  Alexandre Legros; Julien Modolo; Samantha Brown; John Roberston; Alex W Thomas
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.